MedTrace Logo

Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma

NCT06837922 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 504

Last updated 2025-04-17

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled Phase III clinical trial on the efficacy and safety of MG-K10 humanized monoclonal antibody injection in adolescent and adult patients with moderate to severe asthma.

Conditions

Interventions

DRUG

MG-K10/Placebo

MG-K10 Humanized Monoclonal Antibody Injection

Sponsors & Collaborators

  • Shanghai Mabgeek Biotech.Co.Ltd

    lead OTHER_GOV

Principal Investigators

  • JingLi L Li, Medical Ph.D · The First Affiliated Hospital of Guangzhou University of Medical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-25
Primary Completion
2027-11-15
Completion
2028-01-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06837922 on ClinicalTrials.gov